Note: Some of these drugs are not in trials yet or are not in trials that we are monitoring for GIST.
|
|
|
|
Targets |
|
|
None, Adriamycin |
Aventis, |
|
|
|
|
Gemzar, Taxotere |
|
|
|
|
|
|
|
|
|
|
|
Temodor |
Schering-Plough |
|
|
|
|
|
|
|
|
|
|
|
AB Science |
|
|
|
|
|
Novartis |
| PKC theta |
| PKC alpha |
| PKC beta |
|
|
|
|
|
Amgen |
|
|
|
|
|
Amgen |
|
|
|
|
Tasigna |
Novartis |
| KIT |
| PDGFRA |
| PDGFRB |
| bcr-abl |
|
|
|
|
|
ARIAD |
|
|
|
|
|
Astex Therapeutics, Ltd. |
|
|
|
|
|
Novartis |
|
|
|
|
|
|
|
|
|
|
|
Sanofi-Aventis |
|
|
|
|
Recentin |
AstraZeneca |
| VEGFR1 |
| VEGFR2 |
| VEGFR3 |
| KIT |
| PDGFRA |
| PDGFRB |
|
|
|
|
Nexavar |
Bayer |
| KIT |
| PDGFRA |
| PDGFRB |
| BRAF |
| Mutant BRAF |
| CRAF |
| VEGFR |
|
|
|
|
Nexavar + Avastin |
Bayer and Genentech |
| KIT (Sorafenib) |
| PDGFR (Sorafenib) |
| VEGFR (Sorafenib) |
| VEGFR (Bevacizumab) |
| BRAF (Sorafenib) |
| mutant BRAF (Sorafenib) |
| CRAF |
|
|
|
|
|
Bayer/ACT BIOTECH |
|
|
|
|
|
Bayer |
| Raf-1 |
| BRAF |
| VEGRF2 |
| VEGFR3 |
| KIT |
| PDGFR |
| RET |
| TIE-2 |
|
|
|
|
Avastin |
Genentech Bio-oncology |
|
|
|
|
|
Novartis |
| PI3K Class I |
| mTOR Raptor |
| mTOR Rictor |
|
|
|
|
|
Novartis |
|
|
|
|
|
Biogen Idec |
|
|
|
|
|
Biogen Idec |
|
|
|
|
|
Biogen Idec |
|
|
|
|
|
Novartis |
|
|
|
|
|
Bristol-Myers Squibb |
|
|
|
|
|
Bristol-Myers Squibb |
|
|
|
|
Sprycel |
Bristol-Myers Squibb |
| KIT |
| bcr-abl |
| SRC family |
| PDGFRB |
| EPHA2 |
| LCK |
| YES |
| FYN |
| SRC |
|
|
|
|
|
Bristol-Myers Squibb |
|
|
|
|
Velcade + Sutent |
Millennium |
|
|
|
|
|
|
|
|
|
|
|
Pfizer |
|
|
|
|
|
Daiichi Sankyo |
| DR5 (TRAIL-R2) (CS-1008) |
| KIT (imatinib & sunitinib) |
| PDGFRA (imatinib & sunitinib) |
| Bcr-abl |
| VEGFRs (sunitinib) |
| FLT3 (sunitinib) |
| CSF-1R (sunitinib) |
| RET (sunitinib) |
|
|
|
|
Sprycel + Avastin |
Bristol Myers-Squibb + Genetech |
| KIT |
| BCR-ABL |
| PDGFRB |
| SRC family |
| EPHA2 |
| VEGFA (Bevacizumab) |
|
|
|
|
|
|
|
|
|
|
Adriamycin + Glivec |
Pharmacia & Upjohn + Novartis |
|
|
|
|
|
Deciphera Pharmaceuticals, LLC |
|
|
|
|
Yondelis |
Johnson & Johnson |
|
|
|
|
Istodax |
Gloucester Pharmaceuticals |
|
|
|
|
|
Piramed |
|
|
|
|
|
Genentech |
|
|
|
|
|
Genentech |
|
|
|
|
|
Genentech |
|
|
|
|
|
GSK |
|
|
|
|
Votrient |
GlaxoSmithKline |
| KIT |
| VEGFR-1, 2, 3 |
| PDGFRA |
| PDGFRB |
|
|
|
|
|
Aventis |
|
|
|
|
|
Novartis/Vernalis |
|
|
|
|
PEG-Intron |
Novartis, Schering |
|
|
|
|
|
Novartis |
| KIT |
| Bcr/Abl |
| PDGFRA |
| PKC alpha |
| PKC beta |
| PKC gamma |
| VEGFR |
| FGFR |
| FLT3 |
|
|
|
|
Gleevec, (RAD001 is not approved in the US) |
Novartis, Novartis |
|
|
|
|
Gleevec, Tasigna |
Novartis + Novartis |
| Both have similar targets |
| KIT |
| Bcr-abl |
| PDGFRA |
| PDGFRB |
|
|
|
|
|
ImClone |
|
|
|
|
|
Insmed |
|
|
|
|
|
Infinity |
|
|
|
|
|
Infinity |
|
|
|
|
|
Kosan Biosciences |
|
|
|
|
|
Keryx |
|
|
|
|
|
Kirin |
|
|
|
|
|
Novartis |
|
|
|
|
|
MedImmune LLC |
| IGF1 |
| IGF2 |
| IGF-1R (indirectly) |
| IR-A (indirectly) |
|
|
|
|
|
Merck |
|
|
|
|
Zolinza |
Merck |
|
|
|
|
|
Millennium |
| KIT |
| FLT3 |
| PDGFRB |
| PDGFRA (possible) |
|
|
|
|
|
SuperGen |
| KIT |
| AXL |
| PDGFRA |
| c-Met |
| Rad51 |
|
|
|
|
|
Novartis |
|
|
|
|
|
Novartis |
|
|
|
|
Sandostatin |
Novartis |
|
|
|
|
|
OSI |
|
|
|
|
|
OSI |
|
|
|
|
|
Novartis |
| PKC alpha |
| KIT |
| PDGFRA |
| PDGFRA (D842V) |
| VEGFR1 |
| VEGFR2 |
| VEGFR3 |
| FLT3 |
| PKC beta |
| PKC gamma |
| FGFR |
|
|
|
|
|
Plexxicon Inc. |
|
|
|
|
|
Plexxicon Inc. |
|
|
|
|
|
|
|
|
|
|
Velcade |
Millennium |
|
|
|
|
|
Novartis |
| VEGFR1 |
| VEGFR2 |
| VEGFR3 |
| KIT |
| PDGFRB |
|
|
|
|
|
ProIX |
|
|
|
|
|
Oncothyreon |
|
|
|
|
|
Topo/Target A/S |
|
|
|
|
|
Hoffmann-La Roche |
|
|
|
|
Afinitor/Certican |
Novartis |
|
|
|
|
|
Genentech/Amgen |
| DR4 (Death receptor 4) |
| DR5 (Death receptor 5) |
|
|
|
|
|
Schering-Plough |
|
|
|
|
|
Semafore |
| PI3K Class 1A |
| DNA-PK |
| mTOR |
| Polo-like 1 kinases |
| PIM1 |
| CK2 |
|
|
|
|
Rapamune |
Wyeth |
|
|
|
|
|
Serenex |
|
|
|
|
|
Novartis |
| SST-1 |
| SST-2 |
| SST-3 |
| SST-5 |
| Somatostatin receptors (SST-1, SST-2, SST-3, SST-5) |
|
|
|
|
|
Synta |
|
|
|
|
Gleevec + Genasense |
Novartis + Genta |
| KIT (Gleevec) |
| PDGFRA (Gleevec) |
| Bcr/abl (Gleevec) |
| Bcl-2 (Genasense) |
|
|
|
|
Gleevec + Proleukin |
Novartis + Novartis |
| KIT (Gleevec) |
| Bcr/abl (Gleevec) |
| PDGFRA (Gleevec) |
| Interleukin-2 (IL-2) |
|
|
|
|
Gleevec |
Novartis |
| KIT |
| bcr-abl |
| abl |
| PDGFRA |
| PDGFRB |
|
|
|
|
Gleevec + Avastin |
Novartis and Genentech |
| KIT (imatinib) |
| VEGFR (bevacizumab) |
| PDGFRA (imatinib) |
| PDGFRB (imatinib) |
| Bcr/Abl (imatinib) |
|
|
|
|
Gleevec |
Novartis + Keryx |
|
|
|
|
Gleevec, Sutent |
Novartis, Pfizer |
| KIT (imatinib & sunitinib) |
| PDGFRA (imatinib & sunitinib) |
| Bcr/Abl (imatinib) |
| VEGFR1 (sunitinib) |
| VEGFR2 (sunitinib) |
| VEGFR3 (sunitinib) |
| FLT3 (sunitinib) |
| CSR-1R (sunitinib) |
| RET (sunitinib) |
|
|
|
|
Sutent |
Pfizer |
| KIT |
| PDGFRA |
| PDGFRB |
| VEGFR1 |
| VEGFR2 |
| VEGFR3 |
| FLT3 |
| CSF-1R |
| RET |
|
|
|
|
|
|
|
|
|
|
Sutent, |
Pfizer, Pfizer |
| KIT (sunitinib) |
| PDGFRA (sunitinib) |
| PDGFRB (sunitinib) |
| IGF1R (CP-751,871) |
| VEGFR1 (sunitinib) |
| VEGFR2 (sunitinib) |
| VEGFR3 (sunitinib) |
| FLT3 (sunitinib) |
| SCF-1R (sunitinib) |
| RET (sunitinib) |
|
|
|
|
Zolinza + Nexavar |
Merck + Bayer |
| KIT |
| PDGFRA |
| PDGFRB |
| BRAF |
| Mutant BRAF |
| CRAF |
| VEGFR |
| HDAC (vorinostat) |
|
|
|
|
|
Exelixis |
|
|
|
|
|
Exelixis |
|
|
|
|
|
Exelixis |
| PI3K Class I |
| mTOR Raptor |
| mTOR Rictor |
| DNA-PK |
|
|
|
|
|
Exexlixis |
|
|